Product
Supplier
Encyclopedia
Inquiry
Peptide powder Retatrutide 99% pure for Body building buy - large image1
Peptide powder Retatrutide 99% pure for Body building buy - image1
Peptide powder Retatrutide 99% pure for Body building buy - image2

Peptide powder Retatrutide 99% pure for Body building

COA

Unit Price: Get Latest Price
Grade:

Pharmaceutical Grade

Content:

99%

Port:

Tianjin

Brand:

aobosi

Packaging:

5mg/vail,10mg/vail,10vails/box

Price valid (until):

2026-04-30

Company Type:
Trader
Location:
China
Qualification:
Main Products:

peptide product

  • Product Description

  • Seller Information

  • Description


      Product Detail  


    Retatrutide developed by pharmaceutical giant Eli Lilly and alternatively known as GGG Tri-agonist, GLP-1/GIP/glucagon tri-agonist, or LY3437943—is an injectable breakthrough poised for FDA approval, with significant potential to treat obesity and diabetes. While it shares similarities with established weight loss therapies like tirzepatide and semaglutide, retatrutide delivers enhanced efficacy. When paired with balanced nutrition, consistent physical activity, and healthy lifestyle adjustments, it not only amplifies weight loss results but also addresses obesity-related comorbidities such as diabetes and hypertension (high blood pressure).

    What sets retatrutide apart from other weight loss medications is its superior effectiveness, driven by three key therapeutic mechanisms:

    **Gastric Inhibitory Polypeptide Receptor (GIPR) Agonism: By activating GIP receptors, retatrutide strengthens appetite control, blocks fat storage, reduces caloric intake, and boosts energy expenditure.
    **Glucagon-Like Peptide 1 Receptor (GLP-1R) Agonism: It supports weight reduction by improving glycemic control—stimulating pancreatic insulin secretion while curbing the release of glucagon, a hormone that elevates blood sugar levels.
    **Glucagon Receptor (GR) Agonism**: Retatrutide further regulates blood glucose by suppressing glucagon release, diminishes food cravings, and increases energy burn, all of which contribute to meaningful weight loss.

    Pls input...

    Items Specifications
    Product name Retatrutide
    Appearance White to off-whtite powerder or loose lumps
    Packing Package or Customized
    Shop Trizepatide-Detailed Image 1

    Certificates

    Basic Info
    Product Name:

    Pharmaceutical Intermediates,Retatrutide,peptide

    Research
    Class:

    Triple agonist — GCGR, GIPR, GLP-1R

    Status:

    Investigational (Phase 3)

    Mechanism:

    Simultaneously activates glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Engineered from the native GIP backbone with amino acid substitutions to confer GCGR and GLP-1R activity.

    EC50 (Human GCGR):

    5.79 nM

    EC50 (Mouse GIPR):

    0.191 nM

    EC50 (Mouse GLP1R):

    0.794 nM

    EC50 (Mouse GCGR):

    2.32 nM

    EC50 (Human GLP1R):

    0.775 nM

    EC50 (Human GIPR):

    0.0643 nM

    Source:

    Jastreboff AM, et al. N Engl J Med. 2023;389(6):514-526.DOI

    Clinical Development:

    NCT04881760; NCT05882045; NCT06354660

    References
    ChEMBL:

    CHEMBL5095485

    DrugBank:

    DB18993

    KEGG DRUG:

    D12430

    PubChem:

    PubChem

    Disclaimer:

    Retatrutide is an investigational compound not yet approved by FDA or EMA. This listing is for industrial and laboratory research use only. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.

  • Seller Information
    Business Type:

    Trader

    Main Products:

    peptide product

    Location:

    Binhai High-tech Zone

    Payment Terms:

    TT against B/L draft before shipment,100% TT in advance

    Average lead Time:

    2

    Total Annual Revenue:

    $1 million-$2.5 million

    Total Employees:

    201-300

    Year of Establishment:

    2025

  • Country Product Purchase Quantity Date Posted
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.